The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 27, No. 7, pp. 827-831.
© 1993 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Struwe, M
Right arrow Articles by Evans, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Struwe, M
Right arrow Articles by Evans, T.

Research Articles

Effect of dronabinol on nutritional status in HIV infection

M Struwe, SH Kaempfer, CJ Geiger, AT Pavia, TF Plasse, KV Shepard, K Ries, and TG Evans

OBJECTIVE: To examine the effect of dronabinol (delta-9-tetrahydrocannabinol) on appetite and nutritional status in patients with symptomatic HIV infection and weight loss. DESIGN: Double-blind, randomized, placebo-controlled, crossover trial with two five-week treatment periods separated by a two-week washout period. Patients received dronabinol 5 mg twice daily before meals or placebo. SETTING: A university-based HIV/AIDS clinic and a large infectious disease private practice largely devoted to care of patients with HIV. PARTICIPANTS: Twelve HIV-infected patients who had had at least a 2.25-kg weight loss participated in the study. Five patients completed the protocol, and seven withdrew (two because of drug intolerance, two because of disease progression, two because of noncompliance, and one because of experimental antiretroviral therapy). MAIN OUTCOME MEASURES: Main outcome measures included caloric intake, weight, percent body fat, serum prealbumin, and symptom distress. RESULTS: During dronabinol treatment, subjects experienced increased percent body fat (one percent, p = 0.04); decreased symptom distress (p = 0.04); and trends toward weight gain (0.5 kg, p = 0.13), increased prealbumin (29.0 mg/L, p = 0.11), and improved appetite score (p = 0.14). CONCLUSIONS: In a selected group of HIV-infected patients with weight loss, short-term treatment with dronabinol may result in improvement in nutritional status and symptom distress.


This article has been cited by other articles:


Home page
 J Int Assoc Physicians AIDS Care (Chic Ill)Home page
E. DeJesus, B. M. Rodwick, D. Bowers, C. J. Cohen, and D. Pearce
Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients
J Int Assoc Physicians AIDS Care (Chic Ill), June 1, 2007; 6(2): 95 - 100.
[Abstract] [PDF]

Home page
 Endocr. Rev.Home page
U. Pagotto, G. Marsicano, D. Cota, B. Lutz, and R. Pasquali
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Endocr. Rev., February 1, 2006; 27(1): 73 - 100.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
S.-S. Yeh and M. W Schuster
Geriatric cachexia: the role of cytokines
Am. J. Clinical Nutrition, August 1, 1999; 70(2): 183 - 197.
[Abstract] [Full Text] [PDF]

Home page
 Nutr Clin PractHome page
C. Fields-Gardner
Invited Review: A Review of Mechanisms of Wasting in HIV Disease
Nutr Clin Pract, October 1, 1995; 10(5): 167 - 176.
[Abstract] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1993 by Harvey Whitney Books Company.